Wegovy vs Mounjaro: an honest, side-by-side comparison

Wegovy and Mounjaro are the two most-asked-about weight medications of the decade. From the outside, they look almost identical — a small weekly injection, a few months of slow dose increases, gradual weight loss that often surprises people with how undramatic it feels. Inside the body, the two molecules behave differently enough that the choice between them is worth understanding properly.

This isn't a verdict piece. It's a side-by-side that respects the fact that 'better' depends on what your body, your insurance, and your prescriber make possible.

The quick answer

At a glance

The numbers above are averages from large randomized trials — STEP for semaglutide and SURMOUNT for tirzepatide. They are useful for orientation, not prediction. Individual response varies far more than the averages suggest.

How they work — and why that matters

Both medications belong to the GLP-1 receptor agonist class. Both mimic a gut hormone that slows stomach emptying, prompts insulin release, and quiets appetite signals in the brain. That shared mechanism is why both produce the now-familiar pattern of smaller portions, earlier fullness, and a reduction in what users call food noise.

Tirzepatide adds a second action. It also binds to the GIP receptor — another gut hormone that, when activated alongside GLP-1, appears to amplify appetite suppression and improve how the body handles fat storage and insulin sensitivity. The biology of GIP is still being worked out; what isn't in question is the clinical signal: in trials, tirzepatide consistently produces more weight loss than semaglutide on average.

More mechanism isn't automatically better mechanism. Some bodies tolerate one signal more easily than two. Some respond to semaglutide remarkably well and to tirzepatide unremarkably. There are no body-wide rules here, only patterns.

Background: what is GLP-1, in plain English →

What the trials actually show

The STEP-1 trial randomized adults with obesity to weekly semaglutide 2.4 mg or placebo. Over 68 weeks, the semaglutide group lost roughly 15% of starting body weight, compared to about 2.4% on placebo.

SURMOUNT-1 looked at tirzepatide at three doses. At the highest dose (15 mg), adults lost approximately 20.9% of body weight over 72 weeks. Lower doses (5 and 10 mg) produced 15% and 19.5% respectively.

The first direct head-to-head — SURMOUNT-5 — compared maximum-tolerated tirzepatide with maximum-tolerated semaglutide in adults with obesity. Tirzepatide produced roughly 20% weight loss versus roughly 14% on semaglutide. The gap was meaningful but not dramatic, and the highest individual responders on either drug looked similar.

Side effects in real life

Side-effect profiles for the two medications overlap heavily. The differences are in degree and detail, not in category.

• Nausea is the single most common early effect for both, especially during dose escalations.
• Constipation appears in a majority of users on both medications; hydration, fiber, and movement help more than supplements alone.
• Reflux is mentioned more often with tirzepatide, possibly tied to the GIP component or slower upper-GI transit.
• Fatigue early on usually traces to undereating, low protein, or low electrolytes rather than the drug itself.
• Both carry warnings about pancreatitis, gallbladder issues, kidney injury from dehydration, and thyroid C-cell tumors observed in rodent studies.

Deeper guide: the most common GLP-1 side effects and what helps →

What they feel like, day to day

Most users describe semaglutide as a steady, slightly muffling sensation — appetite quietly lower, food less interesting, an unfamiliar comfort with smaller meals. Tirzepatide tends to be described as stronger in degree: deeper satiety, more pronounced loss of interest in trigger foods, and for some, a sharper edge on the first few days after an injection.

These are generalizations. There are heavy tirzepatide users with mild experiences and semaglutide users who describe profound changes. Personal biology beats brand averages every time.

Stronger isn't always better. The right medication is the one your body tolerates well enough to actually stay on.

Cost and access

Both medications are expensive without insurance coverage. Coverage varies by plan, country, employer, and the indication being treated. In some markets, manufacturers offer patient-assistance programs that meaningfully reduce out-of-pocket cost; in others, supply has been the bigger issue than price.

Compounded versions of semaglutide and tirzepatide exist in some markets and have grown rapidly as a response to shortages. Compounded products are not FDA-approved formulations; their potency, sterility, and ingredients can vary, and several regulatory actions have followed. Treat that pathway with significantly more caution than the branded products.

Who might reasonably prefer each one

Wegovy may suit you if…

• You're sensitive to GI side effects and want the slowest possible titration.
• Insurance covers semaglutide but not tirzepatide.
• You've responded well to it previously, or are continuing from Ozempic for diabetes.
• Reflux is a known issue and you want to minimize the chance of it worsening.

Mounjaro (or Zepbound) may suit you if…

• Your prescriber is targeting a larger average weight reduction or combined metabolic improvement.
• You've plateaued on semaglutide despite a well-managed plan.
• Insurance favors tirzepatide or you have access through a diabetes indication.
• You've tolerated semaglutide well and want the dual mechanism's potential added effect.

These are starting points for a conversation with a prescriber. They are not recommendations.

Switching between them

Switching from semaglutide to tirzepatide (or the reverse) is common and well-tolerated when done thoughtfully. Most clinicians restart at the lowest dose of the new medication and titrate up, partly to limit GI side effects and partly because tolerance to one molecule doesn't automatically transfer.

Tracking what changes after a switch matters more than usual: appetite pattern, sleep, energy, symptoms, weight trend. The first six weeks tell a much more honest story than the first week.

How to track your GLP-1 journey beyond the scale →

Muscle, training, and composition

Both medications produce some loss of lean mass as part of total weight loss — a feature of any rapid weight loss, not a specific failure of the drugs. Studies suggest 25–40% of lost weight can be lean tissue without intervention; with resistance training and adequate protein, that share drops substantially.

Two to three full-body strength sessions a week plus roughly 0.7–1 g of protein per pound of goal body weight is the most-cited approach. The medication will lower the weight; the training and the protein will shape what's underneath.

What happens long-term

Long-term data are clearer for semaglutide simply because it has been around longer. The STEP-5 extension showed weight loss largely maintained at two years on continued treatment. SELECT showed a 20% reduction in major cardiovascular events in adults with overweight or obesity and pre-existing cardiovascular disease — a finding that has changed how prescribers think about the class beyond weight.

Tirzepatide's longer-term outcomes data are accumulating. Both medications are being studied across an expanding range of conditions: sleep apnea, fatty liver, kidney disease, and chronic heart failure with preserved ejection fraction. The story is still being written.

So — which one wins?

Neither. The honest answer is that the right medication is the one a prescriber agrees is appropriate for you, that your insurance helps you stay on, that your body tolerates well, and that you actually take consistently. The molecule matters less than that combination.

If you find yourself caught between options, the most useful thing you can do isn't to keep reading comparisons — it's to track the medication you're on now. Six weeks of honest data about energy, symptoms, hydration, and weight trend will tell you more than another article ever will.